• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • 2021-22 Strategic Plan
    • History
    • National Forum Awards
    • Team
    • Support
  • Collaborations
    • Awareness Months 2023
    • Counter Cholesterol™
    • Flu Prevention
    • Know Your Numbers
    • Million Hearts®
      • Million Hearts® Stakeholders Flu Vaccination Campaign ’22
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
      • Value & Innovation Forum
  • Events
    • National Forum and Member Events
    • Health Equity Benefits Everyone – January 2023
    • 2022 Annual Meeting
    • 2022 Mid-Year Virtual Convening
    • 2021 Annual Meeting
    • 2021 Mid-Year Virtual Convening
    • Heart Failure Roundtable
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Annual Meeting
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

National Forum Statement about ICER’s Announced Assessment of New Cholesterol Medications

Posted on 06.12.20

The National Forum released the following statement about the Institute for Clinical and Economic Review’s (ICER’s) announcement today that it will conduct value assessments of inclisiran and bempadoic acid, two new treatments for high cholesterol. The Value & Access Steering Committee (VASC), convened by the National Forum and representing patients, clinical providers, public health, payers and purchasers, has provided input to ICER on several of its assessments. We are pleased that ICER continues to seek input from the VASC and National Forum members.

Analyses of the health and economic impacts of therapies can be valuable to society when they are evidence-based and include input from different stakeholders. The National Forum and the Value & Access Steering Committee will collaborate with ICER to ensure the inclusion of input from patients, clinical providers, public health, payers and purchasers in ICER’s review of new cholesterol-lowering therapies, inclisiran and bempadoic acid.

Click here to see ICER’s announcement.

The National Forum is a nonprofit organization with over 100 public, private and nonprofit sector members. Its mission is to lead and encourage collaborative action among stakeholders committed to heart disease and stroke prevention. The National Forum’s overarching goal is to eliminate cardiovascular health disparities and achieve health equity.

 

Categories: In the News, News Releases, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2023 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter
  • YouTube
Contact

"*" indicates required fields

Name * Required
This field is for validation purposes and should be left unchanged.